PROCEPT BioRobotics Corporation - Common Stock (PRCT)
17.69
+1.00 (5.99%)
NASDAQ· Last Trade: Jul 27th, 9:34 PM EDT
Detailed Quote
Previous Close
16.69
Open
16.97
Bid
16.85
Ask
18.30
Day's Range
16.86 - 18.14
52 Week Range
16.67 - 56.87
Volume
1,344,446
Market Cap
-
PE Ratio (TTM)
-10.35
EPS (TTM)
-1.7
Dividend & Yield
N/A (N/A)
1 Month Average Volume
1,521,225
Chart
About PROCEPT BioRobotics Corporation - Common Stock (PRCT)
Procept Biorobotics Corp is a medical technology company focused on advancing minimally invasive surgical solutions, particularly for the treatment of benign prostate hyperplasia. The company develops innovative robotic-assisted platforms that enhance the precision and effectiveness of procedures, empowering urologists to deliver better patient outcomes while reducing recovery times. Procept aims to transform standard surgical practices through its cutting-edge technology, improving the overall experience for both patients and healthcare providers. Read More
The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, inclusive (“the Class Period”).
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until September 22, 2026 to file lead plaintiff applications in a securities class action lawsuit against PROCEPT BioRobotics Corporation ("Procept" or the "Company") (NasdaqGM: PRCT), if they purchased the Company’s shares between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California.
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased PROCEPT BioRobotics Corporation (“PROCEPT” or the “Company”) (NASDAQ: PRCT) securities between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”). PROCEPT investors have until September 22, 2026 to file a lead plaintiff motion.
Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) between February 28, 2024 and February 25, 2026, inclusive (the “Class Period”). PROCEPT is a medical technology company.
NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the common stock of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) between February 28, 2024 and February 25, 2026, inclusive.
The DJS Law Group reminds investors of a class action lawsuit against PROCEPT BioRobotics Corporation (“Procept” or “the Company”) (NASDAQ: PRCT) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against PROCEPT BioRobotics Corporation (“Procept” or “the Company”) (NASDAQ: PRCT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Robbins LLP informs investors that a securities class action has been filed on behalf of all purchasers of PROCEPT BioRobotics Corporation (NASDAQ: PRCT) common stock between February 28, 2024 and February 25, 2026, inclusive (the "Class Period").
AUSTIN, Texas, July 15, 2026 (GLOBE NEWSWIRE) -- Mobia Medical, Inc. (Nasdaq: MOBI), a commercial-stage medical device company redefining stroke recovery for survivors living with life-altering motor impairments, today announced the appointment of Reza Zadno, Ph.D., to the Board as an independent director, effective July 14, 2026. Dr. Zadno will also serve as a member of the Compensation Committee.
SAN JOSE, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today announced it will report financial results for the second quarter of 2026 after market close on Tuesday, August 4, 2026. The Company’s management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.
SAN JOSE, Calif., May 28, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) today announced two milestones in its WATER IV prostate cancer clinical program: completion of enrollment in the randomized WATER IV study evaluating Aquablation® therapy versus radical prostatectomy, and FDA Investigational Device Exemption (IDE) approval for a second randomized protocol evaluating Aquablation therapy versus active surveillance.
SAN JOSE, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, announced today that members of management will present at three upcoming investor conferences in May and June.
SAN JOSE, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative solutions in urology, today reported unaudited financial results for the quarter ended March 31, 2026.
Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, continues its investigation on behalf of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) investors concerning the Company’s possible violations of the federal securities laws.
Law Offices of Howard G. Smith continues its investigation on behalf of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz continues its investigation of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT) on behalf of investors concerning the Company’s possible violations of federal securities laws.
